Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/9/2025

Management of Pre-Malignant Cervical Lesions

CIN 1 Management

  • The American College of Obstetricians and Gynecologists recommends observation over immediate treatment for CIN 1 preceded by ASC-US, ASC-H, or LSIL cytology, given the >90% spontaneous regression rate within 24 months 1
  • For CIN 1, surveillance options include HPV DNA testing every 12 months or repeat cervical cytology every 6-12 months, with colposcopy indicated if HPV DNA test remains positive at 12 months or repeat cytology shows ASC-US or greater 1, 3, 4
  • The American College of Obstetricians and Gynecologists suggests return to routine screening after negative HPV test at 12 months or two consecutive negative cytology results 1, 4

CIN 2/3 Management

  • High-grade lesions (CIN 2/3) require definitive treatment with either excisional or ablative therapies, with excisional procedures preferred when colposcopy is unsatisfactory or endocervical sampling contains CIN 2, 3, 5, 6
  • The American Society for Colposcopy and Cervical Pathology recommends treatment modalities such as loop electrosurgical excision procedure (LEEP), cold-knife conization (CKC), laser conization, cryotherapy, laser ablation, electrofulguration, and cold coagulation for CIN 2/3 2, 3, 5, 6
  • Excisional procedures carry a 70% increased risk of subsequent preterm delivery, making ablative therapy preferable when feasible for women desiring future fertility 4

Post-Treatment Surveillance

  • For CIN 2/3 with negative margins, the American College of Obstetricians and Gynecologists recommends cervical cytology at 6 months or HPV DNA testing at 12 months 2, 4
  • After ablative procedures, surgical margins cannot be assessed, requiring cervical cytology at 6 months or HPV DNA testing at 12 months 2, 4

HPV Vaccination

  • The American College of Obstetricians and Gynecologists strongly recommends HPV vaccination for women undergoing treatment for precancerous cervical lesions, resulting in 64.9% efficacy in preventing new cervical lesions and 88.2% post-treatment risk reduction of new lesions 7
  • Optimal timing for HPV vaccination is at diagnosis or before cervical conization 7